{"id":"tp-53412","type":"article-newspaper","title":"Oruka Therapeutics Posts $0.63 Q3 GAAP Loss Per Share, Matching Estimates","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/53412","datePublished":"2026-11-10T23:51:50.000Z","dateModified":"2026-11-10T23:51:50.000Z","language":"en","abstract":"Cash, cash equivalents and marketable securities totaled $1.2 billion as of Sept. 30, 2026. Quarterly operating cash use was $44.3 million, compared with $21.6 million a year earlier.","section":"Business","references":[]}